CJC-1295 with DAC 5MG: Research Peptide Information and Product Specifications

CJC-1295 with DAC 5MG is a synthetic peptide analogue of growth hormone-releasing hormone (GHRH) that has attracted scientific interest because of its relationship with endocrine signaling and growth hormone regulation. One of its defining characteristics is the Drug Affinity Complex (DAC) modification, which distinguishes it from non-DAC CJC-1295 formulations.

Presented in a 5 mg format, CJC-1295 with DAC is a research-labeled peptide intended for laboratory and scientific investigation. Understanding its molecular structure, scientific background, and formulation characteristics is important when evaluating this research compound.

What Is CJC-1295 with DAC?

CJC-1295 with DAC is a modified synthetic peptide developed from growth hormone-releasing hormone. It is designed to interact with GHRH receptors involved in the regulation of growth hormone signaling.

The compound contains a Drug Affinity Complex modification that allows it to associate with circulating proteins, particularly albumin. This modification influences its pharmacokinetic characteristics compared with shorter-acting GHRH analogues.

CJC-1295 with DAC is therefore an important subject in scientific investigations examining peptide modifications, protein binding, and endocrine signaling.

Understanding the Drug Affinity Complex (DAC)

The Drug Affinity Complex is a modification that distinguishes CJC-1295 DAC from its non-DAC counterpart.

The modification promotes reversible binding to albumin, a major protein found in blood plasma. Albumin association can influence how long a compound remains in circulation.

This characteristic is one reason CJC-1295 with DAC has received attention in pharmacological research.

It is important to understand that CJC-1295 with DAC and CJC-1295 NO DAC are different formulations. They have distinct structural and pharmacokinetic characteristics and should not be treated as interchangeable products.

CJC-1295 with DAC 5MG Product Specifications

The CJC-1295 with DAC 5MG designation identifies the peptide and its labeled quantity.

Important product specifications include:

• Product name: CJC-1295 with DAC.
• Product quantity: 5 mg as labeled.
• Compound classification: Synthetic research peptide.
• Peptide background: GHRH analogue.
• Distinctive feature: Drug Affinity Complex modification.
• Research focus: GHRH signaling and peptide pharmacokinetics.

Researchers should verify the complete chemical identity, molecular structure, and labeled quantity through manufacturer documentation.

Scientific Research and Growth Hormone Signaling

Growth hormone-releasing hormone is involved in regulating growth hormone secretion through interactions with receptors in the pituitary gland.

CJC-1295 with DAC has been investigated in scientific research involving GHRH receptor activity and the effects of peptide modifications on circulation and biological activity.

Its albumin-binding characteristics make it particularly relevant to studies examining peptide stability and pharmacokinetic behavior.

These investigations contribute to a broader understanding of synthetic peptide development and endocrine signaling.

However, scientific findings do not automatically establish clinical benefits or the safety of research-labeled products.

Quality Control and Laboratory Documentation

Quality assurance is an important consideration when evaluating research peptide materials.

For CJC-1295 with DAC 5MG, researchers should review available documentation, including:

• Verified chemical identity.
• Molecular structure and formulation details.
• Batch or lot identification.
• Purity and analytical testing results.
• Certificate of Analysis (COA).
• Manufacturer and production information.

A batch-specific COA can provide valuable information about analytical testing and product traceability.

Transparent documentation helps researchers evaluate the stated characteristics of laboratory materials.

Storage and Handling Considerations

Peptide stability can vary according to molecular structure, formulation, and environmental conditions.

CJC-1295 with DAC 5MG should be stored and handled according to manufacturer-provided instructions.

General laboratory considerations include maintaining suitable environmental conditions, protecting the original packaging, preserving batch identification, and following appropriate laboratory safety procedures.

Always consult product-specific storage documentation rather than assuming that all peptide formulations have identical requirements.

Important Research Disclaimer

CJC-1295 with DAC 5MG is presented as a research-labeled peptide for laboratory and scientific investigation. It is not an approved medication or dietary supplement. Its relationship with growth hormone signaling does not establish safety or effectiveness for human or veterinary use, anti-aging, bodybuilding, or treatment of medical conditions.

This description is informational and does not recommend self-administration or consumption. Research materials should be evaluated according to applicable regulations and laboratory safety standards.

Conclusion

CJC-1295 with DAC 5MG is a synthetic GHRH analogue distinguished by its Drug Affinity Complex modification. Its albumin-binding characteristics and relationship with growth hormone signaling have made it a subject of scientific and pharmacological research.

When evaluating this peptide, prioritize verified chemical identification, transparent product specifications, batch traceability, analytical documentation, and responsible laboratory practices.